JP4100805B2 - Cosmetics - Google Patents
Cosmetics Download PDFInfo
- Publication number
- JP4100805B2 JP4100805B2 JP05305299A JP5305299A JP4100805B2 JP 4100805 B2 JP4100805 B2 JP 4100805B2 JP 05305299 A JP05305299 A JP 05305299A JP 5305299 A JP5305299 A JP 5305299A JP 4100805 B2 JP4100805 B2 JP 4100805B2
- Authority
- JP
- Japan
- Prior art keywords
- oil
- acid
- effect
- seed oil
- oils
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002537 cosmetic Substances 0.000 title description 17
- 230000004907 flux Effects 0.000 claims description 26
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 26
- 230000008099 melanin synthesis Effects 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 18
- 229940069445 licorice extract Drugs 0.000 description 18
- 239000003921 oil Substances 0.000 description 18
- 235000019198 oils Nutrition 0.000 description 18
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 12
- 239000003925 fat Substances 0.000 description 12
- 235000019197 fats Nutrition 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 230000003078 antioxidant effect Effects 0.000 description 11
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- TUYRNAGGIJZRNM-LBHUVFDKSA-N [(2s)-2-[(2r)-4-hexadecanoyloxy-3-hydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(OC(=O)CCCCCCCCCCCCCCC)=C1O TUYRNAGGIJZRNM-LBHUVFDKSA-N 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 150000000996 L-ascorbic acids Chemical class 0.000 description 8
- -1 hyaluronic acid Chemical class 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 206010003645 Atopy Diseases 0.000 description 7
- 206010012438 Dermatitis atopic Diseases 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 7
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 7
- 201000008937 atopic dermatitis Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 229960004488 linolenic acid Drugs 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 6
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 6
- 229940090949 docosahexaenoic acid Drugs 0.000 description 6
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 6
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 6
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000002087 whitening effect Effects 0.000 description 6
- 229940058015 1,3-butylene glycol Drugs 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 235000019437 butane-1,3-diol Nutrition 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 239000008351 acetate buffer Substances 0.000 description 4
- 235000013871 bee wax Nutrition 0.000 description 4
- 239000012166 beeswax Substances 0.000 description 4
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 244000303040 Glycyrrhiza glabra Species 0.000 description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 229940087168 alpha tocopherol Drugs 0.000 description 3
- 229960000271 arbutin Drugs 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000014593 oils and fats Nutrition 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000036962 time dependent Effects 0.000 description 3
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 3
- 229960000984 tocofersolan Drugs 0.000 description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 3
- 239000002076 α-tocopherol Substances 0.000 description 3
- 235000004835 α-tocopherol Nutrition 0.000 description 3
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 239000008278 cosmetic cream Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 235000004426 flaxseed Nutrition 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000000199 molecular distillation Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical group CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 239000004261 Ascorbyl stearate Substances 0.000 description 1
- LITUBCVUXPBCGA-WMZHIEFXSA-N Ascorbyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O LITUBCVUXPBCGA-WMZHIEFXSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- NMZKLLJQNNTBRJ-OIXZZONUSA-N TXA3 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)C\C=C/CC)O[C@@H]2O[C@H]1C2 NMZKLLJQNNTBRJ-OIXZZONUSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 235000019276 ascorbyl stearate Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Inorganic materials [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 230000009290 primary effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Cosmetics (AREA)
Description
【0001】
【産業上の利用分野】
本発明は、シス型α−リノレン酸を豊富に含有するフラックスシードオイルと油溶性甘草エキス、アスコルビン酸誘導体の1種または2以上を含有し、酸化による安定性に優れると共に抗炎症効果、荒れ肌改善効果、美白効果が高く、アトピー性皮膚炎に対しても優れた効果を発揮する化粧料に関するものである。
【0002】
【従来の技術】
従来から荒れ肌の改善には、保湿性に重点を置いた化粧料が多く開発されていた。 すなわち、セラミドを配合したものや、ヒアルロン酸等の多糖類また、コラーゲン、エラスチンなどのペプチド類を配合したものが開発されてきた。 しかし、これらの化粧料では、一次的な効果はあるものの、継続的に充分な効果が得られていないのが現状である。
【0003】
また、アトピー性皮膚炎は、皮膚疾患の中で最も多い疾患の一つであるが、治療剤としては主として副腎皮質ホルモンや、非ステロイド性抗炎症剤、抗ヒスタミン剤が用いられている。 しかし、副作用の問題などもあり、充分な効果を挙げているとはいいがたい。
【0004】
最近では、同じくn−3系列に属するα−リノレン酸を含有するシソ油がアトピー性皮膚炎に対して用いられている。 しかし、現在使用されているシソ油の中には、精製過程で加熱され天然型のシス型からトランス型に変わっているものが多く見受けられる。 一般に生体内の細胞膜は、シス型脂肪酸で構成されており、トランス型α−リノレン酸は細胞膜の膜構成を乱すと考えられ、健康面への問題が議論されている。
【0005】
さらに、α−リノレン酸に限らずn−3系列に属するエイコサペンタエン酸やドコサヘキサエン酸を多く含む油脂類が利用されているが、これらの油脂類は不飽和結合が多いため経時的に酸化が進み易い。 そのため、従来はα−トコフェロール等の抗酸化剤を添加し酸化を防止していたが、変臭や変色等の問題があり、充分な効果を発揮し得なかった。
【0006】
【発明が解決しようとする課題】
本発明は上記問題点を解決すべくなされたものであり、有効成分としてシス型α−リノレン酸を豊富に含有するフラックスシードオイル等の不飽和脂肪酸と油溶性甘草エキス、アスコルビン酸誘導体の1種または2以上を含有することにより、酸化防止効果が高く、抗炎症効果、荒れ肌改善効果、美白効果やアトピー性皮膚炎に対して優れた効果を発揮する化粧料に関するものである。
【0007】
【課題を解決するための手段】
すなわち、有効成分としてn−3系列に属するα−リノレン酸を豊富に含むフラックスシードオイルおよびエイコサペンタエン酸やドコサヘキサエン酸を多く含む油脂類と油溶性甘草エキス、アスコルビン酸誘導体の1種または2以上を含有することを特徴とする、抗酸化効果が高く荒れ肌改善化粧料や、アトピー性皮膚炎に有効な化粧料を提供するものである。
【0008】
最近において、アトピー性皮膚炎が多くなった背景の一つに、食生活の欧米化があげられる。 タンパク源の摂取が魚から肉類中心になったため、体内に取り込まれる脂肪酸の割合が、魚類に多く含まれるn−3系列の脂肪酸から、肉類に多く含まれるn−6系列の脂肪酸に変化してきた。
【0009】
n−6系列の脂肪酸は、生体内で代謝されてロイコトリエン4系列、プロスタグランジン2系列、トロンボキサンA2など、アレルギーを初めとする炎症性メデイエーターに変化する。 一方、n−3系列の脂肪酸からはロイコトリエン5系列、プロスタグランジン3系列、トロンボキサンA3など、n−6系列の脂肪酸代謝物に比べ、炎症活性の強さが数分の一から、数十分の一の代謝物に変化する。 そのため、炎症に対する生体の炎症反応が弱くなり、皮膚での炎症が緩和され、肌荒れ、アトピーの症状が緩和されることとなる。
【0010】
本発明で用いられるフラックスシードオイルは、無農薬栽培された亜麻仁種子を33〜40℃以下の低温で圧搾したもので、α−リノレン酸を57%以上含むものである。 また、フラックスシードオイル以外のn−3系列に属するエイコサペンタエン酸やドコサヘキサエン酸を多く含む油脂類は、魚類から圧搾して得たものである。 ただし、フラックスシードオイルの採取の方法はこれに限られるものではなく、臨界ガス抽出法、溶剤による抽出法、等の油脂を抽出する方法として公知の方法を採用することができる。 また、フラックスシードオイル以外のn−3系列に属するエイコサペンタエン酸やドコサヘキサエン酸を多く含む油脂類は、微生物を培養し菌体中に生産された油脂を抽出して得る方法などによっても得ることができる。
【0011】
さらに、本発明で用いられる油溶性甘草エキスは、甘草の根を有機溶媒で抽出したものである。 有機溶媒による調製法は特に限定されないが、例えば種々の適当な有機溶媒を用いて低温下から加温下で抽出される。 抽出溶媒としては、例えば、メチルアルコール、エチルアルコール等の低級1価アルコール;グリセリン、プロピレングリコール、1,3−ブチレングリコール等の液状多価アルコール;アセトン、メチルエチルケトン等のケトン;酢酸エチルなどのアルキルエステル;ベンゼン、ヘキサン等の炭化水素;ジエチルエーテル等のエーテル類;ジクロルメタン、クロロホルム等のハロゲン化アルカン等の1種または2種以上を用いることが出来る。 就中、エチルアルコール、酢酸エチルの1種または2種以上の混合溶媒が特に好適である。
【0012】
また、本発明で用いられるアスコルビン酸誘導体は、L−アスコルビル−2−リン酸ナトリウム、L−アスコルビル−2−リン酸マグネシウム、L−アスコルビル−2−リン酸カリウム、L−アスコルビル−2−リン酸カルシウム、L−アスコルビル−2−硫酸ナトリウム、L−アスコルビル−2−硫酸カリウム、L−アスコルビル−2−硫酸マグネシウム、L−アスコルビル−2−硫酸カルシウム、ステアリン酸アスコルビル、パルミチン酸アスコルビルおよび、ジパルミチン酸アスコルビル等のモノおよび、ジ脂肪酸のアスコルビン酸エステル類が挙げられるがこれに限定されるものではない。
【0013】
本発明の化粧料に配合されるフラックスシードオイル及びn−3系列の不飽和脂肪酸の配合量は特に限定されないが、0.01%〜100%の配合が好ましく、特に0.1%〜30%が最適である。0.01%以下では期待する効果が得られにくいからである。 また、油溶性甘草エキス、アスコルビン酸誘導体の配合量は特に限定されないが、油脂類に対して0.01%〜10%の配合が好ましく、特に0.1%〜1%が最適である。
0.01%以下では油脂類の酸化防止効果が得られにくいからである。
【0014】
本発明の化粧料は、上記必須成分のほか、化粧品、医薬部外品、医薬品に用いられる水性成分、油性成分、植物抽出物、動物抽出物、粉末、界面活性剤、油剤、アルコール、PH調整剤、防腐剤、酸化防止剤、増粘剤、色素、香料等を必要に応じて混合して適宜配合することにより調製される。 本発明の化粧料の剤形は特に限定されず、化粧水、乳液、クリーム、パック、パウダー、スプレー、軟膏、分散液、洗浄料等種々の剤形とすることができる。
【0015】
【実施例】
以下、本発明にかかわる油溶性甘草エキス、アスコルビン酸誘導体の油脂類の酸化防止効果について述べるが、ここに記載された実施例に限定されないのは言うまでもない。
【0016】
【実施例1】
試料類の調整
フラックスシードオイルは、亜麻仁の種4を室温で圧搾機にかけ、絞った油を室温でときどき撹拌しながら7日間静置した後、油層を分離し分子蒸留により精製した。 また、フラックスシードオイル以外のn−3系列に属するエイコサペンタエン酸やドコサヘキサエン酸を多く含む油脂類は、魚類から圧搾し、得られた油を分子蒸留により精製して得た。 油溶性甘草エキスは、甘草(Glycyrrhiza glabra L.)の根をエタノールで抽出後乾燥し、乾燥物をさらに酢酸エチルで抽出したものである。 また、アスコルビン酸誘導体としては試薬として市販されている、アスコルビン酸ジパルミテートを用いた。
【0017】
【実施例2】
油溶性甘草エキスの酸化防止効果
油溶性甘草エキスの油脂類の酸化防止効果を測定するために、油脂類に各種の酸化防止剤を添加し、チオバルビツール酸によるTBARSの測定を行った。 なお、試験期間を短縮するため、それぞれの試料を60℃に放置し、加速試験を行った。
酸化防止剤としては、α−トコフェロール、油溶性甘草エキス、アスコルビン酸ジパルミテートを表−1の量、それぞれ添加して試験を行った。
【0018】
試薬調製
(a)酢酸緩衝液:氷酢酸20mlを水に溶かし100mlとし、10N−NaOHを用いてPH3.5にする。
(b)0.67% チオバルビツール酸酢酸緩衝液:チオバルビツール酸0.67gを上記酢酸緩衝液100mlに溶解させる。
(c)0.8%BHT酢酸溶液:ジブチルヒドロキシトルエン(BHT)0.8gを氷酢酸100mlに溶解させる。
(d)n−ブタノール:試薬特級
【0019】
測定
試料0.2mlを試験管に取り、酢酸緩衝液1.5ml、0.8%BHT酢酸溶液0.05ml、0.67%TBA酢酸緩衝液1.5ml、精製水0.7mlを加える。その後沸騰水浴中に60分間放置し、反応させる。 冷却後n−ブタノール5.0mlを加え、撹拌後遠心分離により上澄みを取る。 分光光度計により、上清の532nmの吸光度を測定する。
【0020】
試験結果
【表1】
フラックスシードオイルの経時的TBARS値
【0021】
表−1にフラックスシードオイルの経時的TBARS値を示した。 従来油脂類の酸化防止剤として使用されているα−トコフェロールや、油溶性のアスコルビン酸と比較して、油溶性甘草エキスの経時的TBARS値が低く、酸化防止効果が高いことがわかる。また、油溶性甘草エキスとアスコルビン酸ジパルミテートの混合系が最も経時的TBARS値が低く、酸化防止効果が高いことがわかった。
【0022】
【実施例3】
つぎにフラックスシードオイルの美白効果について、マウスメラノーマ細胞によるメラニン産生抑制試験について述べるが、ここに記載された実施例に限定されないのは言うまでもない。
【0023】
試料の調製
フラックスシードオイル150ppm、ポリオキシエチレン硬化ヒマシ油 500ppm、 牛胎児血清10%の割合になるようにそれぞれの試料を評取し良く溶解した後、ダルベッコMEM培養液に加える。 培養液を超音波処理により透明にした後、除菌濾過をし試料を調製する。
【0024】
細胞培養
マウスメラノーマ細胞B−16株を用いて、実験を行った。 培地にはダルベッコMEM培養液に牛胎児血清10%を添加した。フラックスシードオイルは培地にそれぞれ25ppm,50ppm,75ppm,100ppmの濃度になるように添加した。また、美白効果の陽性対照物質としてアルブチンを用いた。 メラニン量の測定は培養後細胞を2N−NaOHに溶解し、400nmの吸光度を測定した。
また、細胞数は2N−NaOHに溶解した細胞溶解液の一部をBio−Rad社のプロテインアッセイキットにより600nmの吸光度で測定した。
【0025】
実験結果
表−2にマウスメラノーマB−16細胞に及ぼすフラックスシードオイルの効果を示した。
陽性対照であるアルブチンは、50ppm以上では細胞毒性がかかるため50ppmの濃度で比較した。 アルブチンが50ppm添加で68%のメラニン産生量であるのに比べ、フラックスシードオイルは、100ppm添加でメラニン産生度が45%であり、高い美白効果が認められた。
【0026】
【表2】
マウスメラノーマB−16細胞に及ぼすフラックスシードオイルの効果
【0027】
つぎにフラックスシードオイルの荒れ肌改善効果、アトピー症状改善効果にかかわる試験実施例を示すと共にその素材を用いた化粧料への応用処方例等について述べるが、ここに記載された実施例に限定されないのは言うまでもない。
【実施例4】
フラックスシードオイルを配合した化粧料の処方例
(1)化粧用クリーム (重量%)
a)フラックスシードオイル‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥15.0
b)ミツロウ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥2.0
c)ステアリルアルコール‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥5.0
d)ステアリン酸‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥5.0
e)自己乳化型グリセリルモノステアレート‥‥‥‥‥‥‥‥‥‥‥‥3.0
f)ポリオキシエチレンセチルエーテル(20E.O.)‥‥‥‥‥‥1.0
g)油溶性甘草エキス‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥0.05
h)アスコルビン酸ジパルミテート‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥0.05
i)1,3−ブチレングリコール‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥5.0
j)水酸化カリウム‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥0.3
k)防腐剤‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥適量
l)精製水‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥残部
製法 a)〜h)までを加熱溶解し、80℃に保つ。i)〜l)までを加熱溶解し、80℃に保ち、a)〜h)に加えて乳化し、40℃まで撹拌する。
(2)化粧用クリーム (重量%)
a)フラックスシードオイル‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥10.0
b)ミツロウ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥2.0
c)ステアリルアルコール‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥5.0
d)ステアリン酸‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥5.0
e)自己乳化型グリセリルモノステアレート‥‥‥‥‥‥‥‥‥‥‥‥3.0
f)ポリオキシエチレンセチルエーテル(20E.O.)‥‥‥‥‥‥1.0
g)油溶性甘草エキス‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥0.05
h)1,3−ブチレングリコール‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥5.0
i)水酸化カリウム‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥0.3
j)防腐剤‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥適量
k)精製水‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥残部
製法 a)〜g)までを加熱溶解し、80℃に保つ。h)〜k)までを加熱溶解し、80℃に保ち、a)〜g)に加えて乳化し、40℃まで撹拌する。
(3)乳液 (重量%)
a)フラックスシードオイル‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥7.0
b)ミツロウ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥1.5
c)ワセリン‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥2.0
d)ソルビタンセスキオレエート‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥0.8
e)ポリオキシエチレンオレイルエーテル(20E.O.)‥‥‥‥‥1.2
f)油溶性甘草エキス‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥0.05
g)アスコルビン酸ジパルミテート‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥0.05
h)1,3−ブチレングリコール‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥7.0
i)カルボキシビニルポリマー‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥0.2
j)水酸化カリウム‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥0.1
k)精製水‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥残部
l)防腐剤‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥適量
m)エタノール‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥7.0
製法 a)〜g)までを加熱溶解し、80℃に保つ。h)〜l)までを加熱溶解し、80℃に保ち、a)〜g)に加えて乳化し、50℃まで撹拌しながら冷却する。50℃でm)を添加し良く撹拌した後、冷却する。
(4)乳液 (重量%)
a)エイコサペンタエン酸‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥7.0
b)ミツロウ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥1.5
c)ワセリン‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥2.0
d)ソルビタンセスキオレエート‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥0.8
e)ポリオキシエチレンオレイルエーテル(20E.O.)‥‥‥‥‥1.2
f)油溶性甘草エキス‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥0.05
g)アスコルビン酸ジパルミテート‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥0.05
h)1,3−ブチレングリコール‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥7.0
i)カルボキシビニルポリマー‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥0.2
j)水酸化カリウム‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥0.1
k)精製水‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥残部
l)防腐剤‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥適量
m)エタノール‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥7.0
製法 a)〜g)までを加熱溶解し、80℃に保つ。h)〜l)までを加熱溶解し、80℃に保ち、a)〜g)に加えて乳化し、50℃まで撹拌しながら冷却する。50℃でm)を添加し良く撹拌した後、冷却する。
(5)化粧水 (重量%)
a)フラックスシードオイル‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥0.5
b)グリセリン‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥5.0
c)ポリオキシエチレンソルビタンモノラウレート(20E.O.)‥1.0
d)油溶性甘草エキス‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥0.01
e)アスコルビン酸ジパルミテート‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥0.01
f)エタノール‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥6.0
g)香料‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥適量
h)防腐剤‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥適量
i)精製水‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥残部
製法 a)〜i)までを混合し、均一に溶解する。
(6)パック剤 (重量%)
a)ドコサヘキサエン酸‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥2.0
b)油溶性甘草エキス‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥0.01
c)アスコルビン酸ジパルミテート‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥0.01
d)酢酸ビニル樹脂エマルジョン‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥15.0
e)ポリビニルアルコール‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥10.0
f)オリーブ油‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥3.0
g)グリセリン‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥5.0
h)酸化チタン‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥8.0
i)カオリン‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥7.0
j)エタノール‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥8.0
k)香料‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥適量
l)防腐剤‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥適量
m)精製水‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥残部
製法a)〜m)までを混合し、よく撹拌、分散させ均一にする。
【0028】
【実施例5】
使用効果試験
本発明の化粧料の荒れ肌改善効果、およびアトピー症状改善効果につき、使用テストにより効果試験を行った。 使用テストは、それぞれ20〜30才の20名の女性をパネラーとし、毎日朝と夜の2回、1ケ月にわたり洗顔後に試験化粧料を顔面に塗布することにより行った。 試験化粧料は、実施例4(1)、(3)、(3)、(5)のクリーム、乳液、化粧水から、フラックスシードオイルをスクワランに置き換えたものを使用した。 結果を表3に示す。 なお、評価基準は下記の基準により評価した。
<評価基準>
・有効‥‥‥肌のかさつきやあれが改善され、アトピー症状が良くなった。
・やや有効‥肌のかさつきやあれがやや改善され、アトピー症状も少し軽くなった。
・無効‥‥‥使用前と変わらない。
【0029】
表3の結果から明らかなように、実施例5の化粧料は皮膚の荒れ肌改善効果、およびアトピー症状改善効果に対し有効であった。
【0030】
【表3】
肌荒れ改善効果
【0031】
【発明の効果】
以上詳述したごとく、本発明化粧料は不飽和脂肪酸を多く含む油脂類の酸化安定生を向上させると共に、皮膚の荒れ肌改善効果、アトピー症状改善効果、および美白効果に優れている。 このため、さまざまな皮膚の炎症の防止等に適用することができ、炎症による肌のくすみや、炎症により荒れた状態の肌を正常に整え、潤いのあるみずみずしい肌に保つことが出来る。[0001]
[Industrial application fields]
The present invention contains flux seed oil rich in cis α-linolenic acid, one or more of oil-soluble licorice extract and ascorbic acid derivative, and has excellent stability due to oxidation, anti-inflammatory effect, and improvement of rough skin The present invention relates to a cosmetic that has a high effect and whitening effect, and also exhibits an excellent effect against atopic dermatitis.
[0002]
[Prior art]
Conventionally, many cosmetics with emphasis on moisture retention have been developed to improve rough skin. In other words, those containing ceramide, those containing polysaccharides such as hyaluronic acid, and peptides such as collagen and elastin have been developed. However, although these cosmetics have a primary effect, the present situation is that a sufficient effect is not continuously obtained.
[0003]
Atopic dermatitis is one of the most common skin diseases, and as a therapeutic agent, corticosteroids, nonsteroidal anti-inflammatory agents, and antihistamines are mainly used. However, there are problems of side effects, and it is hard to say that they are sufficiently effective.
[0004]
Recently, perilla oil containing α-linolenic acid, also belonging to the n-3 series, has been used for atopic dermatitis. However, among the perilla oils currently in use, there are many that have been heated in the refining process and changed from the natural cis form to the trans form. In general, a cell membrane in a living body is composed of cis-type fatty acid, and trans-type α-linolenic acid is considered to disturb the membrane configuration of the cell membrane, and health problems have been discussed.
[0005]
Furthermore, not only α-linolenic acid but also fats and oils containing a large amount of eicosapentaenoic acid and docosahexaenoic acid belonging to the n-3 series are used. However, these fats and oils have many unsaturated bonds, and oxidation progresses over time. easy. Therefore, conventionally, an antioxidant such as α-tocopherol has been added to prevent oxidation, but there are problems such as odor and discoloration, and sufficient effects cannot be exhibited.
[0006]
[Problems to be solved by the invention]
The present invention has been made to solve the above-mentioned problems, and is one of unsaturated fatty acids such as flux seed oil, oil-soluble licorice extract, and ascorbic acid derivatives that are rich in cis-type α-linolenic acid as an active ingredient. Alternatively, by containing 2 or more, the present invention relates to a cosmetic that has a high antioxidant effect and exhibits an excellent anti-inflammatory effect, rough skin improving effect, whitening effect, and atopic dermatitis.
[0007]
[Means for Solving the Problems]
That is, one or more of a flux seed oil rich in α-linolenic acid belonging to the n-3 series as an active ingredient, an oil and fats rich in eicosapentaenoic acid and docosahexaenoic acid, an oil-soluble licorice extract, and an ascorbic acid derivative The present invention provides a cosmetic for improving rough skin and effective for atopic dermatitis, which has a high antioxidant effect, and is effective for atopic dermatitis.
[0008]
One of the reasons for the recent increase in atopic dermatitis is the westernization of eating habits. Since the intake of protein sources has shifted from fish to meat, the proportion of fatty acids taken into the body has changed from n-3 fatty acids that are abundant in fish to n-6 fatty acids that are abundant in meat. .
[0009]
The n-6 series fatty acids are metabolized in vivo to change into inflammatory mediators including allergies such as leukotriene 4 series, prostaglandin 2 series, thromboxane A 2 and the like. On the other hand, the intensity of inflammatory activity is less than a few fractions of n- 3 series fatty acids compared to n-6 series fatty acid metabolites such as leukotriene 5 series, prostaglandin 3 series, thromboxane A 3 and the like. It turns into one-tenth metabolite. Therefore, the inflammatory reaction of the living body with respect to inflammation becomes weak, inflammation in the skin is relieved, and rough skin and atopic symptoms are relieved.
[0010]
The flux seed oil used in the present invention is obtained by pressing flaxseed seeds grown without agrochemicals at a low temperature of 33 to 40 ° C. and contains 57% or more of α-linolenic acid. Oils and fats containing a large amount of eicosapentaenoic acid and docosahexaenoic acid belonging to the n-3 series other than the flux seed oil are obtained by pressing from fish. However, the method of collecting the flux seed oil is not limited to this, and a known method can be adopted as a method for extracting fats and oils such as a critical gas extraction method and a solvent extraction method. In addition, oils and fats containing a large amount of eicosapentaenoic acid and docosahexaenoic acid belonging to the n-3 series other than flux seed oil can be obtained by a method of cultivating microorganisms and extracting oils and fats produced in the cells. it can.
[0011]
Furthermore, the oil-soluble licorice extract used in the present invention is obtained by extracting licorice root with an organic solvent. Although the preparation method by an organic solvent is not specifically limited, For example, it extracts under low temperature from heating using various suitable organic solvents. Examples of the extraction solvent include lower monohydric alcohols such as methyl alcohol and ethyl alcohol; liquid polyhydric alcohols such as glycerin, propylene glycol, and 1,3-butylene glycol; ketones such as acetone and methyl ethyl ketone; alkyl esters such as ethyl acetate. 1 type or 2 types or more, such as hydrocarbons, such as benzene and hexane; Ethers, such as diethyl ether; Halogenated alkanes, such as dichloromethane and chloroform, can be used. In particular, one or more mixed solvents of ethyl alcohol and ethyl acetate are particularly suitable.
[0012]
Moreover, ascorbic acid derivatives used in the present invention are L-ascorbyl-2-phosphate, L-ascorbyl-2-magnesium phosphate, L-ascorbyl-2-potassium phosphate, L-ascorbyl-2-calcium phosphate, L-ascorbyl-2-sodium sulfate, L-ascorbyl-2-potassium sulfate, L-ascorbyl-2-magnesium sulfate, L-ascorbyl-2-calcium sulfate, ascorbyl stearate, ascorbyl palmitate, ascorbyl dipalmitate, etc. Ascorbic acid esters of mono- and di-fatty acids are not limited thereto.
[0013]
The blending amount of the flux seed oil and the n-3 unsaturated fatty acid blended in the cosmetic of the present invention is not particularly limited, but is preferably 0.01% to 100%, particularly 0.1% to 30%. Is the best. This is because it is difficult to obtain the expected effect at 0.01% or less. Moreover, although the compounding quantity of an oil-soluble licorice extract and an ascorbic acid derivative is not specifically limited, 0.01%-10% of compounding with respect to fats and oils is preferable, and 0.1%-1% are especially optimal.
It is because the antioxidant effect of fats and oils is hard to be obtained at 0.01% or less.
[0014]
In addition to the above essential ingredients, the cosmetics of the present invention are cosmetics, quasi-drugs, aqueous ingredients used in pharmaceuticals, oily ingredients, plant extracts, animal extracts, powders, surfactants, oils, alcohols, pH adjustments. An agent, an antiseptic, an antioxidant, a thickener, a coloring matter, a fragrance, and the like are mixed as necessary and mixed appropriately. The dosage form of the cosmetic of the present invention is not particularly limited, and can be various dosage forms such as lotion, milky lotion, cream, pack, powder, spray, ointment, dispersion, and detergent.
[0015]
【Example】
Hereinafter, although the oil-soluble licorice extract and the ascorbic acid derivative according to the present invention will be described in terms of the antioxidant effects of fats and oils, it is needless to say that the present invention is not limited to the examples described herein.
[0016]
[Example 1]
Preparation of Samples Flux seed oil was prepared by putting flaxseed seed 4 in a press at room temperature and allowing the squeezed oil to stand for 7 days with occasional stirring at room temperature, then separating the oil layer and purifying by molecular distillation. Moreover, fats and oils containing a lot of eicosapentaenoic acid and docosahexaenoic acid belonging to the n-3 series other than the flux seed oil were obtained by pressing from fish and purifying the obtained oil by molecular distillation. The oil-soluble licorice extract is obtained by extracting the roots of licorice (Glycyrrhiza glabra L.) with ethanol and then drying, and further extracting the dried product with ethyl acetate. As the ascorbic acid derivative, ascorbic acid dipalmitate commercially available as a reagent was used.
[0017]
[Example 2]
Antioxidant effect of oil-soluble licorice extract In order to measure the antioxidant effect of fats and oils of oil-soluble licorice extract, various antioxidants were added to fats and oils, and TBARS was measured with thiobarbituric acid. In order to shorten the test period, each sample was left at 60 ° C., and an accelerated test was performed.
As the antioxidant, α-tocopherol, oil-soluble licorice extract, and ascorbic acid dipalmitate were added in the amounts shown in Table 1, respectively.
[0018]
Reagent preparation (a) Acetic acid buffer: Dissolve 20 ml of glacial acetic acid in water to make 100 ml, and adjust to pH 3.5 using 10N NaOH.
(B) 0.67% thiobarbituric acid acetate buffer: 0.67 g of thiobarbituric acid is dissolved in 100 ml of the above acetate buffer.
(C) 0.8% BHT acetic acid solution: 0.8 g of dibutylhydroxytoluene (BHT) is dissolved in 100 ml of glacial acetic acid.
(D) n-butanol: reagent grade
Take 0.2 ml of a measurement sample in a test tube, and add 1.5 ml of acetate buffer, 0.05 ml of 0.8% BHT acetic acid solution, 1.5 ml of 0.67% TBA acetate buffer, and 0.7 ml of purified water. Then, it is left to react in a boiling water bath for 60 minutes. After cooling, 5.0 ml of n-butanol is added, and after stirring, the supernatant is removed by centrifugation. The absorbance of the supernatant at 532 nm is measured with a spectrophotometer.
[0020]
Test results [Table 1]
Temporal TBARS value of flux seed oil [0021]
Table 1 shows the time-dependent TBARS values of the flux seed oil. It can be seen that the oil-soluble licorice extract has a low time-dependent TBARS value and a high antioxidant effect as compared with α-tocopherol and oil-soluble ascorbic acid that have been used as antioxidants for conventional fats and oils. Moreover, it turned out that the mixed system of oil-soluble licorice extract and ascorbic acid dipalmitate has the lowest time-dependent TBARS value and the high antioxidant effect.
[0022]
[Example 3]
Next, the whitening effect of the flux seed oil will be described with respect to a melanin production suppression test using mouse melanoma cells, but it goes without saying that the present invention is not limited to the examples described herein.
[0023]
Sample preparation Each sample is evaluated and dissolved well so that the ratio of flux seed oil 150 ppm, polyoxyethylene hydrogenated castor oil 500 ppm, and fetal calf serum 10% is added to the Dulbecco MEM culture solution. The culture solution is clarified by ultrasonic treatment, and then subjected to sterilization filtration to prepare a sample.
[0024]
Experiments were performed using cell culture mouse melanoma cell line B-16. To the medium, 10% fetal calf serum was added to Dulbecco's MEM culture solution. The flux seed oil was added to the medium so as to have concentrations of 25 ppm, 50 ppm, 75 ppm, and 100 ppm, respectively. Arbutin was used as a positive control substance for whitening effect. The amount of melanin was measured by dissolving cells in 2N-NaOH after culture and measuring the absorbance at 400 nm.
The number of cells was determined by measuring a part of the cell lysate dissolved in 2N-NaOH at an absorbance of 600 nm using a protein assay kit manufactured by Bio-Rad.
[0025]
Experimental results Table 2 shows the effect of flux seed oil on mouse melanoma B-16 cells.
Arbutin, which is a positive control, was compared at a concentration of 50 ppm because cytotoxicity is required at 50 ppm or more. Compared to the melanin production amount of 68% when arbutin was added at 50 ppm, the flux seed oil had a melanin production rate of 45% when 100 ppm was added, and a high whitening effect was recognized.
[0026]
[Table 2]
Effect of flux seed oil on mouse melanoma B-16 cells
Next, test examples related to rough skin improvement effect and atopy symptom improvement effect of flux seed oil will be shown and application prescription examples to cosmetics using the material will be described, but it is not limited to the examples described here. Needless to say.
[Example 4]
Formulation example of cosmetics containing flux seed oil (1) Cosmetic cream (wt%)
a) Flux seed oil …………………………………………………… 15.0
b) Beeswax ………………………………………………………………………………… 2.0
c) Stearyl alcohol ……………………………………………………………… 5.0
d) Stearic acid …………………………………………………………………………………… 5.0
e) Self-emulsifying glyceryl monostearate ……………………………………………… 3.0
f) Polyoxyethylene cetyl ether (20E.O.) ... 1.0
g) Oil-soluble licorice extract ………………………………………………………………………………………………………… 0.05
h) Ascorbic acid dipalmitate …………………………………………………………… 0.05
i) 1,3-Butylene glycol ………………………………………………………… 5.0
j) Potassium hydroxide ………………………………………………………………………………………… 0.3
k) Preservatives ……………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………. …………………………………………………………………………………………………………. Heat up to i) to l), keep at 80 ° C., add to a) to h), emulsify, and stir to 40 ° C.
(2) Cosmetic cream (wt%)
a) Flux seed oil …………………………………………………………………… 10.0
b) Beeswax ………………………………………………………………………………… 2.0
c) Stearyl alcohol ……………………………………………………………… 5.0
d) Stearic acid …………………………………………………………………………………… 5.0
e) Self-emulsifying glyceryl monostearate ……………………………………………… 3.0
f) Polyoxyethylene cetyl ether (20E.O.) ... 1.0
g) Oil-soluble licorice extract ………………………………………………………………………………………………………… 0.05
h) 1,3-Butylene glycol ………………………………………………………… 5.0
i) Potassium hydroxide ……………………………………………………………………………… 0.3
j) Preservatives ……………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… …………………………………………………………………………………………. Heat up to h) to k), keep at 80 ° C., add to a) to g), emulsify, and stir to 40 ° C.
(3) Emulsion (wt%)
a) Flux seed oil ……………………………………………………………… 7.0
b) Beeswax ····································· 1.5
c) Petrolatum ········································· 2.0
d) Sorbitan sesquioleate …………………………………………………………… 0.8
e) Polyoxyethylene oleyl ether (20E.O.) 1.2
f) Oil-soluble licorice extract …………………………………………………………………………………………………………………… 0.05
g) Ascorbic acid dipalmitate …………………………………………………………… 0.05
h) 1,3-Butylene glycol ……………………………………………………… 7.0
i) Carboxyvinyl polymer …………………………………………………………………… 0.2
j) Potassium hydroxide …………………………………………………………………………………… 0.1
k) Purified water ………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… ………………………………………………………………………………………………………………………………………………………………………………………… 7.0
The production methods a) to g) are dissolved by heating and kept at 80 ° C. Heat up to h) to l), keep at 80 ° C., add to a) to g), emulsify, and cool to 50 ° C. with stirring. Add m) at 50 ° C. and stir well, then cool.
(4) Emulsion (wt%)
a) Eicosapentaenoic acid …………………………………………………………… 7.0
b) Beeswax ····································· 1.5
c) Petrolatum ········································· 2.0
d) Sorbitan sesquioleate …………………………………………………………… 0.8
e) Polyoxyethylene oleyl ether (20E.O.) 1.2
f) Oil-soluble licorice extract …………………………………………………………………………………………………………………… 0.05
g) Ascorbic acid dipalmitate …………………………………………………………… 0.05
h) 1,3-Butylene glycol ……………………………………………………… 7.0
i) Carboxyvinyl polymer …………………………………………………………………… 0.2
j) Potassium hydroxide …………………………………………………………………………………… 0.1
k) Purified water ………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… ………………………………………………………………………………………………………………………………………………………………………………………… 7.0
The production methods a) to g) are dissolved by heating and kept at 80 ° C. Heat up to h) to l), keep at 80 ° C., add to a) to g), emulsify, and cool to 50 ° C. with stirring. Add m) at 50 ° C. and stir well, then cool.
(5) Lotion (wt%)
a) Flux seed oil …………………………………………………………………………………… 0.5
b) Glycerin ……………………………………………………………………………………………… 5.0
c) Polyoxyethylene sorbitan monolaurate (20E.O.) 1.0
d) Oil-soluble licorice extract …………………………………………………………………………………………………
e) Ascorbic acid dipalmitate ………………………………………………………………… 0.01
f) Ethanol ………………………………………………………………………………………… 6.0
g) Fragrances ………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… ……………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………. Mix up to i) and dissolve uniformly.
(6) Packing agent (wt%)
a) Docosahexaenoic acid ………………………………………………………………………………… 2.0
b) Oil-soluble licorice extract ……………………………………………………………………………………………
c) Ascorbic acid dipalmitate ………………………………………………………………… 0.01
d) Vinyl acetate resin emulsion · · · · · · · · · · · · · · · 15.0
e) Polyvinyl alcohol ………………………………………………………………………… 10.0
f) Olive oil ……………………………………………………………………………………………… 3.0
g) Glycerin ………………………………………………………………………………………… 5.0
h) Titanium oxide ········································ 8.0
i) Kaolin …………………………………………………………………………………………… 7.0
j) Ethanol …………………………………………………………………………………………………… 8.0
k) Fragrance ………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… ……………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………. Mix until m), and stir and disperse well until uniform.
[0028]
[Example 5]
Use effect test About the rough skin improvement effect of the cosmetics of this invention, and the atopy symptom improvement effect, the effect test was done by the use test. The use test was carried out by applying 20 females, each 20-30 years old, as a panelist and applying test cosmetics to the face after face washing twice a day in the morning and at night for one month. The test cosmetics used were the creams, emulsions, and lotions in Example 4 (1), (3), (3), and (5), in which the flux seed oil was replaced with squalane. The results are shown in Table 3. The evaluation criteria were evaluated according to the following criteria.
<Evaluation criteria>
・ Effective ………… Improves skin roughness and roughness, and improves atopic symptoms.
・ Slightly effective …… Skin softness and that were slightly improved, and atopic symptoms were slightly reduced.
・ Invalid ... The same as before use.
[0029]
As is apparent from the results in Table 3, the cosmetic of Example 5 was effective for improving the rough skin and atopic symptoms.
[0030]
[Table 3]
Rough skin improvement effect [0031]
【The invention's effect】
As described in detail above, the cosmetic of the present invention improves the oxidation stability of fats and oils containing a large amount of unsaturated fatty acids, and is excellent in rough skin improvement effect, atopic symptom improvement effect, and whitening effect. For this reason, it can be applied to prevent various skin irritation, etc., and the skin dullness caused by the inflammation and the skin roughened by the inflammation can be properly prepared and kept moist and fresh.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP05305299A JP4100805B2 (en) | 1999-01-22 | 1999-01-22 | Cosmetics |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP05305299A JP4100805B2 (en) | 1999-01-22 | 1999-01-22 | Cosmetics |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000212060A JP2000212060A (en) | 2000-08-02 |
JP4100805B2 true JP4100805B2 (en) | 2008-06-11 |
Family
ID=12932102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP05305299A Expired - Lifetime JP4100805B2 (en) | 1999-01-22 | 1999-01-22 | Cosmetics |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4100805B2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001122733A (en) * | 1999-10-26 | 2001-05-08 | Noevir Co Ltd | Catalase production-promoting preparation and skin preparation for external use containing the same |
JP2001261570A (en) * | 2000-03-22 | 2001-09-26 | Nisshin Oil Mills Ltd:The | Skin care preparation |
US6881427B2 (en) * | 2002-01-31 | 2005-04-19 | Alticor Inc. | Topical anti-inflammatory composition containing linseed and licorice extracts |
DE10224387A1 (en) | 2002-06-01 | 2003-12-11 | Beiersdorf Ag | Cosmetic or dermatological preparations with a prepared extract from Radix Glycyrrhizae inflatae |
EP1648405A1 (en) * | 2003-05-30 | 2006-04-26 | Isomers Laboratories Inc. | Cosmetic with flax seed extract as carrier |
EP1656935A1 (en) * | 2004-11-12 | 2006-05-17 | Cognis IP Management GmbH | Use of physiologically active fatty acids for the treatment of pruritus |
TW200808333A (en) * | 2006-04-17 | 2008-02-16 | Kaneka Corp | Licorice polyphenol preparation |
DE102012211030A1 (en) | 2012-06-27 | 2014-01-02 | Beiersdorf Ag | Use of creatine for lightening cosmetic preparation comprising active ingredients with natural color |
-
1999
- 1999-01-22 JP JP05305299A patent/JP4100805B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP2000212060A (en) | 2000-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4299374B2 (en) | Cell activator and its application | |
FR2725370A1 (en) | COSMETIC OR DERMATOLOGICAL COMPOSITION CONTAINING AN OIL RICH IN PETROSELINIC ACID | |
KR101352363B1 (en) | Composition of skin external application for moisturizing comprising Scrophularia buergeriana Miq. extract | |
FR2826579A1 (en) | COSMETIC COMPOSITION CONTAINING AT LEAST ONE OIL EXTRACTED FROM CUCURBITACEOUS SEEDS, ITS COSMETIC, THERAPEUTIC AND FOOD USE | |
JP4100805B2 (en) | Cosmetics | |
JP2008088075A (en) | Profilaggrin/filaggrin production promoter, epidermal keratinocyte proliferation promoter, skin care preparation for normalizing epidermis/horny cell layer, profilaggrin/filaggrin production-promoting method and epidermal keratinocyte proliferation-promoting method | |
JP3808947B2 (en) | Oily solid cosmetic | |
JP2019065004A (en) | Skin normal flora improving agent and cosmetic or skin external preparation containing the same | |
JP2990611B2 (en) | Extraction method for dandruff growth inhibitory components | |
JPH07277920A (en) | Cosmetic containing steam-distilled water and/or extract of lemongrass | |
KR20000065305A (en) | Skin care composition containing stabilized retinol, phytosphingosine, and Castaneae crenata extracts | |
JP6723979B2 (en) | Wrinkle improver | |
JP7644411B2 (en) | Composition for controlling skin flora | |
JP4457133B2 (en) | External preparation for skin and whitening agent | |
JP5155543B2 (en) | Endothelin-1 production inhibitor, hexosaminidase release inhibitor, anti-inflammatory / whitening skin preparation, endothelin-1 production inhibition method, and hexosaminidase release inhibition method | |
KR100368126B1 (en) | Composition capable of inhibiting sebum secretion | |
JP3935636B2 (en) | Skin and mind cosmetics | |
JP4037836B2 (en) | Hyaluronidase activity inhibitor | |
JP2000327570A (en) | External preparation for skin | |
JP2000143527A (en) | Hyaluronic acid production promoter and skin preparation for external use containing the same | |
JPH08119829A (en) | External medicine for skin | |
KR102503007B1 (en) | A composition for promoting the differentiation of human adipose derived stem cell | |
JP5144048B2 (en) | Radical scavenger, antioxidant skin external preparation, and radical scavenging method | |
JP2007176878A (en) | NF-kappaB ACTIVATION INHIBITOR AND EXTERNAL PREPARATION COMPOSITION I CONTAINING THE SAME | |
JP2004137166A (en) | Skin care preparation for external use, cell activator and antioxidant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060111 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060216 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20070222 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070306 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070507 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071225 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080205 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080311 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080318 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110328 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110328 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120328 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130328 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130328 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140328 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |